Genovis introduces a new service concept

Genovis is launching a service through which customers can order antibody
fragmentation with “Smart Enzymes,” thereby opens a new market niche for the
company's products.
Genovis’ products are marketed under the name “Smart Enzymes” and are used to
process antibodies and split them into smaller fragments. To date, the products
have been marketed primarily for characterization of biologics. Customers use
small quantities of the products in a large number of samples to divide the drug
candidate into smaller fragments, which are then analyzed. All of the products
are also highly effective with production of larger amounts of antibody
fragments, which are required in several different studies in preclinical drug
discovery. Genovis is now also focusing on this market and is launching a
service through which customers order antibody fragmentation.

Implementation of new technology often requires resources. Buying the products
that are necessary to fragment large quantities of antibodies represents an
investment for the customer. By offering this service, Genovis can provide
customers with quick results and facilitate technology transfer to the customer,
thereby minimizing the customer’s technology-associated risk and costs for the
actual project. Subsequently, the customer can choose to continue to have
Genovis do the work, or buy the required products and carry out the project in
-house. Genovis has met a need and has worked closely with customers on projects
in the past. Now the company will take the concept to the next stage and
actively offer the service as part of its range of services to existing and new
customers.

“Our knowledge about our enzymes and the fact that we can process and analyze
them on a routine basis allows us to provide high-quality quick results. We have
extensive cumulative expertise in-house, and that knowledge is extremely
valuable for customers who are new to both the products and the technology. Our
service generates revenue by quickly bridging the technology transfer gap to
customers and in the long term will open up a new market niche for our products.
The combination with our endotoxin-free products allows us to focus on a broad
target group for both in vitro and in vivo tests in studies such as target
validation in the pharmaceutical industry. Offering a service is completely in
line with our strategy for developing new markets in collaboration with our
customers,” says Sarah Fredriksson, CEO of Genovis
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00